Company news

Cardiff Oncology, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer

July 11, 2021

Cardiff Oncology to Participate in a Fireside Chat at the William Blair Biotech Focus Conference 2021

July 5, 2021

Cardiff Oncology Added to the Russell 2000® and other FTSE Russell Indexes

June 27, 2021

Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors

June 9, 2021

Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer

June 7, 2021

Cardiff Oncology Announces First Quarter 2021 Results and Recent Highlights

May 5, 2021

Cardiff Oncology Announces Onvansertib Phase 1b/2 Data that Continues to Demonstrate Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRC

April 11, 2021

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2021

March 9, 2021

Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights

February 24, 2021

Cardiff Oncology Receives "Study May Proceed" from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

January 25, 2021

Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board

December 20, 2020

Cardiff Oncology Announces Third Quarter 2020 Results and Highlights

November 4, 2020

Cardiff Oncology Prices Public Offering

September 28, 2020

Cardiff Oncology Announces Proposed Public Offering

September 28, 2020

Cardiff Oncology Announces Second Quarter 2020 Results and Highlights

August 10, 2020

Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML

June 14, 2020

Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation

June 8, 2020

Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer

May 27, 2020

Cardiff Oncology Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn Bioventures

May 26, 2020

Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer

May 18, 2020

Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer

May 5, 2020

← Newer news releases

Calls

Decks

The 5 newest of 89 decks. Every deck is listed under its year.